David Zawitz - 25 Nov 2025 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role
Chief Operating Officer
Signature
/s/ Jayson Rieger, Attorney-in-Fact
Issuer symbol
VRCA
Transactions as of
25 Nov 2025
Net transactions value
+$42,425
Form type
4
Filing time
25 Nov 2025, 19:00:13 UTC
Previous filing
09 Dec 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zawitz David Chief Operating Officer C/O VERRICA PHARMACEUTICALS INC., 44 W. GAY ST., SUITE 400, WEST CHESTER /s/ Jayson Rieger, Attorney-in-Fact 25 Nov 2025 0002046750

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRCA Common Stock Purchase $42,425 +10,000 +91% $4.24 21,000 25 Nov 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRCA Series C Warrant (right to buy) Purchase +2,500 2,500 25 Nov 2025 Common Stock 2,500 $6.32 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective July 24, 2025, the Issuer effected a 1-for-10 reverse stock split of the Issuer's common stock. The number of securities reported herein have been adjusted to reflect the reverse stock split.
F2 Immediately exercisable.
F3 The reported securities are included within 10,000 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.